Summary
BeOne Medicines Ltd. (ONC), now known as BeiGene, Ltd., announced a significant strategic collaboration on April 9, 2019, with BioAlta, LLC. This partnership focuses on the global co-development, manufacturing, and commercialization of BioAlta's investigational Conditionally Active Biologic CTLA-4 antibody, identified as BA3071. This move represents a key step in expanding BeiGene's pipeline and potential therapeutic offerings in the competitive oncology space.
Key Highlights
- 1BeOne Medicines (BeiGene) enters a global co-development and collaboration agreement with BioAlta, LLC.
- 2The collaboration centers on BioAlta's investigational CTLA-4 antibody, BA3071.
- 3The agreement covers development, manufacturing, and commercialization of BA3071.
- 4This partnership expands BeiGene's oncology pipeline with a novel biologic therapy.
- 5The press release detailing the agreement was issued on April 9, 2019, and filed with the SEC on April 10, 2019.